Obesity is biology, not a character flaw
Your body defends its weight with hormones — hunger that returns, metabolism that slows, cravings that win. Modern medicine finally treats those signals directly. Here's how, without the jargon.
A GLP-1 receptor agonist — a peptide engineered to mimic your own satiety hormone
One signal, three organs
GLP-1 class therapy works on the gut, brain and pancreas at once — watch the signal travel.
Brain
Appetite ↓ · Fullness ↑
Gut
GLP-1 signal after meals · slower gastric emptying
Pancreas
Insulin only when glucose is high
The gut speaks first
After you eat, your intestine releases GLP-1 — a hormone that says "we're fed". GLP-1 class medications mimic this signal, but last days instead of minutes, and also slow how fast your stomach empties so meals keep you full longer.
The brain stops shouting
GLP-1 receptors in the hypothalamus quieten appetite and 'food noise'. Cravings shrink not because you're fighting them, but because the signal driving them is regulated.
The pancreas gets smarter
Insulin is released only when glucose is actually high — improving metabolic control without the crash-and-crave cycle. That's why this class also transformed type 2 diabetes care.
Set-point, satiety hormones, insulin response — your weight is regulated by systems, and systems can be treated.
Your body has a set-point — and it fights to keep it
Cut calories hard and your metabolism slows, hunger hormones surge, and within months most weight returns. That's not weak willpower — it's homeostasis. Supervised therapy lowers the set-point pressure itself, so nutrition and strength work finally stick.
- Doses start low and titrate up over 8–12 weeks to minimise nausea.
- Weekly check-ins watch vitals, side effects and muscle preservation.
- Protein-forward Indian nutrition plans — dal, paneer, eggs, not imported salads.
Your metabolic picture
Live previewResting metabolic rate (kcal)
Activity score
12-month weight target
Illustrative curve based on published clinical-trial outcomes of GLP-1 class therapy with lifestyle support. Individual results vary.
Indian bodies need Indian thresholds
At the same BMI, South Asians carry more visceral fat and higher metabolic risk than Western populations — so Indian guidance acts earlier.
27.5
Obese
Asian-Indian cut-offs: overweight from BMI 23, obese from 27
Who qualifies for supervision
- BMI ≥ 27 — treatment may be considered on medical grounds alone.
- BMI ≥ 25 + a comorbidity — type 2 diabetes, hypertension, high cholesterol or sleep apnea.
- Below these thresholds, medication offers little benefit — we'll tell you so and point you to lifestyle-first care.
What the trials actually show
Across large randomised trials, GLP-1 class therapy with lifestyle support achieved roughly triple the weight reduction of lifestyle programs alone — with effects on blood pressure, glucose and lipids that matter more than the number on the scale.
GLP-1 class therapy + lifestyle support
−15%average body-weight reduction in phase-3 trials (~68 weeks)
Lifestyle changes alone
−5%typical sustained reduction with diet & exercise programs
Unsupervised fad diets
−2%weight commonly regained within 12 months
Illustrative summary of published clinical literature on GLP-1 receptor agonist class therapy. Individual results vary; no outcome is guaranteed.
Supervision is the active ingredient
Trials succeed because patients are monitored, doses are titrated and side effects are managed early. That's the part Clinoble replicates — a doctor who actually follows up, not a one-time prescription.
Who we won't treat online — by design
These contraindications are screened in the quiz before anyone pays a rupee. If any apply, we route you to in-person care instead.
If clinically appropriate, the doctor may prescribe treatment — never guaranteed.